Alliance Trust Plc Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Alliance Trust Plc reduced its stake in Amgen by 3.47% during the most recent quarter end. The investment management company now holds a total of 664,924 shares of Amgen which is valued at $110,157,959 after selling 23,900 shares in Amgen , the firm said in a disclosure report filed with the SEC on Jul 20, 2016.Amgen makes up approximately 4.96% of Alliance Trust Plc’s portfolio.

Other Hedge Funds, Including , First American Bank boosted its stake in AMGN in the latest quarter, The investment management firm added 6,130 additional shares and now holds a total of 9,992 shares of Amgen which is valued at $1,655,375. Amgen makes up approx 0.16% of First American Bank’s portfolio.Berkshire Asset Managementpa reduced its stake in AMGN by selling 11,952 shares or 13.89% in the most recent quarter. The Hedge Fund company now holds 74,109 shares of AMGN which is valued at $12,098,294. Amgen makes up approx 1.79% of Berkshire Asset Managementpa’s portfolio.Telemus Capital boosted its stake in AMGN in the latest quarter, The investment management firm added 361 additional shares and now holds a total of 19,814 shares of Amgen which is valued at $3,234,636. Amgen makes up approx 0.37% of Telemus Capital’s portfolio. Merriman Wealth Management added AMGN to its portfolio by purchasing 160,823 company shares during the most recent quarter which is valued at $25,908,585. Amgen makes up approx 7.22% of Merriman Wealth Management’s portfolio.

Amgen opened for trading at $162.45 and hit $163.65 on the upside on Wednesday, eventually ending the session at $163.25, with a gain of 0.47% or 0.76 points. The heightened volatility saw the trading volume jump to 21,61,425 shares. Company has a market cap of $122,636 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.